Logo

U of Liverpool Center Joins Roche NimbleGen CSP Program

Oct 22, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Roche today announced that the Centre for Genomic Research at the University of Liverpool in the UK has joined the Roche NimbleGen Certified Service Provider program.

As a result, CGR is certified to perform next-generation sequencing target enrichment services with customer samples using the NimbleGen SeqCap EZ workflow. Roche said that CGR is the first facility authorized in the UK to provide SeqCap EZ target enrichment services.

Roche discontinued its NimbleGen microarray business in 2012 but continued to develop and sell sequence capture products. In April, the company also said that it was shutting down its Applied Science Business Area. BioArray News reported at the time, though, that the sequence capture business would not be affected by the change.

Filed under

Clinical Sequencing
Sequencing
Microarrays & Multiplexing
Business News
certified service provider
microarrays
Next-Generation Sequencing
Roche
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.